Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes

Diabetes

Volumn 49, Issue 1, 2000, Pages 32-38

  Pietropaolo, Massimo ^a   Barinas Mitchell, Emma ^b   Pietropaolo, Susan L ^a   Kuller, Lewis H ^b   Trucco, Massimo ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AUTOANTIBODY; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; INSULIN;

ACUTE PHASE RESPONSE; AGED; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0033970353     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.1.32     Document Type: Article

References (57)

1. Harris MI: Epidemiology of diabetes mellitus among the elderly in the United States. Clin Geriatr Med 6:703-719, 1990
2. Scheen AJ: Non-insulin-dependent diabetes mellitus in the elderly. Baillières Clin Endocrinol Metab 11:389-407, 1997
3. Pugh JA, Katz MS: Geriatrics and diabetes mellitus. In Current Management of Diabetes Mellitus. DeFronzo RA, Ed. St. Louis, MO, Mosby, 1998, p. 255-261
4. Bottazzo GF, Florin-Christensen A, Doniach D: Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet ii:1279-1282, 1974
5. Baekkeskov S, Aanstoot H, Christgau S, Reetz A, Solimena MS, Cascalho M, Folli F, Richter-Olsen H, DeCamilli P: Identification of the 64K autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347:151-156, 1990
6. Irvine WJ, Gray RS, McCallum CJ, Duncan LJP: Clinical and pathogenic significance of pancreatic-islet-cell-antibodies in diabetics treated with oral hypoglycemic agents. Lancet i:1025-1027, 1977
7. Groop L, Bottazzo GF, Doniach D: Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 35:237-241, 1986
8. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles WJ, Mackay IR: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes in adults with a non-insulin-dependent onset of diabetes. Diabetes 42:359-362, 1993
9. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R, for the UK Prospective Diabetes Study (UKPDS) Group: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350:1288-1293, 1997
10. Tuomi T, Carlsson Å, Li H, Isomaa B, Miettien A, Nilssoon A, Nissén M, Ehrnström B-O, Forsén B, Snickarss B, Lahti K, Forsblom C, Saloranta C, Taskinen M-R, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157, 1999
11. Alberti KGMM, Zimmet PZ, for the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
12. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang A: Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11:299-303, 1994
13. → diabetes with residual β-cell function. Diabetes Care 22:615-617, 1999
14. Rewers M, Hamman RF: Risk factors for non-insulin dependent diabetes. In Diabetes in America. 2nd ed. Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, Eds. Washington, DC, U.S. Govt. Printing Office, 1995 (NIH publ. no. 95-1468), p. 179-220
15. Kahn CR: Banting Lecture: Insulin action, diabetogenes and the cause of type II diabetes. Diabetes 43:1066-1084, 1994
16. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 272:50-54, 1996
17. Medzhitov R, Janeway CA: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9:4-9, 1997
18. McMillan DE: Increased levels of acute-phase serum proteins in diabetes. Metabolism 38:1042-1046, 1989
19. Ganda OP, Arkin CF: Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care 15:1245-1250, 1992
20. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
21. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
22. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA: IL-1 produced and released endogenously within human islets inhibits β cell function. J Clin Invest 102:516-526, 1998
23. Alexander RW: Inflammation and coronary artery disease. N Engl J Med 331:468-469, 1994
24. Rabin DU, Pleasic SM, Shapiro JA, Yoo-Warren H, Oles J, Hicks JM, Goldstein DE, Rae PMM: Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 152:3183-3188, 1994
25. Lan MS, Lu J, Goto Y, Notkins AL: Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 13:505-514, 1994
26. Tell GS, Fried LP, Lind B, Manolio TA, Newman AB, Borhani NO: Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 3:358-366, 1993
27. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB: The cardiovascular health study: design and rationale. Ann Epidemiol 1:263-276, 1991
28. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP: Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 41:264-270, 1995
29. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
30. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L, Karlsen AE, Boel E, Michelsen B, Lernmark A: A novel radiobinding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 37:344-350, 1994
31. Gianani R, Rabin DU, Verge CF, Yu L, Babu SR, Pietropaolo M, Eisenbarth GS: ICA512 autoantibody radioassay. Diabetes 44:1340-1344, 1995
32. Pietropaolo M, Hutton JC, Eisenbarth GS: Protein-tyrosine phosphatase-like proteins: link with insulin-dependent diabetes mellitus. Diabetes Care 20:208-214, 1997
33. Kawasaki E, Eisenbarth GS, Wasmeier C, Hutton JC: Autoantibodies to protein tyrosine phosphatase-like proteins in type 1 diabetes: overlapping specificities to phogrin and ICA512/IA-2. Diabetes 45:1344-1349, 1996
34. Clauss A: Gerinnungs physiologische schnellmethods zur bestimmung des fibrinogens. Acta Haemost 17:237-246, 1957
35. Macy E, Hayes T, Tracy RP: Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin Chem 43:52-58, 1997
36. Arkkila PET, Kantola IM, Viikari JSA: Limited joint mobility in non-insulin-dependent diabetic (NIDDM) patients: correlation to control of diabetes, atherosclerotic vascular disease, and other diabetic complications. J Diabetes Complications 11:208-217, 1997
37. Jennings PE: Oral antihyperglycaemics: considerations in older patients with non-insulin-dependent diabetes mellitus. Drug Ther 10:323-331, 1997
38. Coopan R: Diabetes in the elderly: implications of the Diabetes Control and Complications Trial. Compr Ther 1996:286-290, 1997
39. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase PH, Eisenbarth GS: Prediction of type I diabetes mellitus in first degree relatives using a combination of insulin, glutamic acid decarboxylase and ICA512bdc/ IA-2 autoantibodies. Diabetes 45:926-933, 1996
40. Pietropaolo M, Peakman M, Pietropaolo SL, Zanone MM, Foley TP, Becker DJ, Trucco M: Combined analysis of GAD65 and ICA512(IA-2) autoantibodies in organ and non-organ specific autoimmune diseases confers high specificity for insulin-dependent diabetes mellitus. J Autoimmun 11:1-10, 1998
41. Ziegler AG, Hummel M, Schenker M, Bonifacio E: Autoantibody appearance and risk for development of childhood diabetes in offspring parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes 48:460-468, 1999
42. Zimmet PZ, Shaten BJ, Kuller LH, Rowley MJ, Knowles WJ, Mackay IR, for the UK Prospective Diabetes Study (UKPDS) Group: Antibodies to glutamic acid decarboxylase and diabetes mellitus in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 140:683-690, 1994
43. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa M: GAD antibodies in NIDDM: ten-year follow-up from the diagnosis. Diabetes Care 18:1557-1565, 1995
44. Pietropaolo M, Libman I, Pietropaolo SL, Gay J, LaPorte RE, Trucco M, Becker DJ: Sequential evaluation of IA-2 and GAD65 autoantibodies in first degree relatives of IDDM patients followed to IDDM (Abstract). Diabetes 46 (Suppl. 1):A196, 1997
45. Bingley PJ, Williams AJK, Gale EA: Stability of autoantibody combinations over time (Abstract). Diabetes 47 (Suppl. 1):A226, 1998
46. Kobayashi T, Nakanishi K, Okubo M, Murase T, Kosaka K: GAD antibodies seldom disappear in slowly progressive IDDM. Diabetes Care 19:1031, 1996
47. Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, Tracy RP, for the Multiple Risk Factor Intervention Trial Research Group: The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 134:1266-1277, 1991
48. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G: Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Int Med 125:653-657, 1996
49. Kuller LH, Tracy RP, Shaten J, Meilahn EN, for the Multiple Risk Factor Intervention Trial Research Group: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 144: 537-547, 1996
50. Corti MC, Salive ME, Guralnik JM: Serum albumin and physical function as predictors of coronary heart disease mortality and incidence in older persons. J Clin Epidemiol 49:519-526, 1996
51. Luoma PV, Näyhä S, Sikkilä K, Hassi J: High serum alpha-tocopherol, albumin, selenium and cholesterol, and low mortality from coronary heart disease in northern Finland. J Int Med 237:49-54, 1994
52. Mantovani A, Bussolino F, Intrano M: Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 18:231-240, 1997
53. Tracy RP, Lemaitre RN, Diane P, Evans RW, Cushman M, Meilahn EN, Kuller LH: Relationship of C-reactive proteins to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17:1121-1127, 1997
54. Tracy RP, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH: Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17:2167-2176, 1997
55. Schmidt MI, Duncan BB, Sharret AR, Lindberg G, Savage PJ, Offenbacher S, Azambujia MI, Tracy RP, Heiss G, for the ARIC Investigators: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 353:1649-1652, 1999
56. Klonhoff-Cohen H, Barrett-Connor EL, Edelstein SL: Albumin levels as a predictor of mortality in the healthy elderly. J Clin Epidemiol 45:207-212, 1992
57. Weijenberg MP, Feskens EJM, Souverrijn JHM, Kromhout D: Serum albumin, coronary heart disease, and mortality in an elderly cohort. Epidemiology 8:87-92, 1997